{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Survival curves for PFS will be estimated using the Kaplan-Meier method. Assessed percentage of participants with progression free survival up to 16 months.","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression\\* or unacceptable toxicity.\n\n\\* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years.\n\nLaboratory Biomarker Analysis: Ancillary studies\n\nPembrolizumab: Given IV","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 16 months","title":"Progression-free Survival (PFS) Using RECIST 1.1","type":"SECONDARY","unitOfMeasure":"% of participants"}